Search for apigenin and colorectal cancer and you will find two systematic reviews with meta-analyses. That sounds like the top of the evidence pyramid. Read the methods sections and both turn out to pool preclinical studies: cell lines in one case, animal models in the other. Neither includes a single human being. That distinction is the most important thing to understand about this literature, and it is almost never stated when the results get summarized.
Key Takeaways
- A 2024 meta-analysis of 39 colorectal studies found consistent benefit, but 37 of those studies were in vitro and only eight involved live animals. None involved patients.
- A 2022 meta-analysis of apigenin in animal cancer models reported large tumor volume reductions and then flagged its own funnel plot asymmetry as evidence of publication bias.
- Apigenin potentiated the chemotherapy drug 5-fluorouracil by suppressing thymidylate synthase, but apoptosis depended on functional p53, which roughly half of colorectal tumors have mutated.
- The only human population data are dietary. In a meta-analysis of 12 epidemiological studies, higher flavone intake tracked with lower rectal cancer risk but not lower colon cancer risk.
- The 5-fluorouracil finding is a reason for oncologist involvement, not a reason for self-supplementation during treatment.
What the Meta-Analyses Actually Pooled
A 2024 systematic review and meta-analysis in Cancer Medicine searched four databases for apigenin and colorectal cancer and included 39 articles on colorectal adenocarcinoma.[1] Thirty-seven contributed in vitro data. Eight contributed in vivo data. Six contributed both. The pooled result was that apigenin reduces cell viability and induces growth inhibition, apoptosis and cell cycle arrest, and that the small number of animal studies showed reduced tumor size without body weight effects.
To their credit, the authors state the limitation plainly in their own conclusion: further in vivo studies are needed before any effort to translate the evidence into clinical studies. Not into clinical practice. Into clinical studies. The research has not reached the stage of asking whether a trial is warranted.
The 2022 meta-analysis in Critical Reviews in Oncology and Hematology covered apigenin across cancer types in animal models, including colon, colorectal and colitis-associated carcinoma among others.[2] Across 25 studies it reported a standardized mean difference for tumor volume of -3.597, with a 95 percent confidence interval of -4.502 to -2.691. Tumor weight, tumor number and tumor load all moved in the same direction, and animal body weight did not change significantly.
Those are large effect sizes. The same paper then notes that the funnel plot showed poor symmetry, which the authors interpret as publication bias, and concludes that further research is warranted. A large pooled effect from a literature with asymmetric publication is exactly the pattern that shrinks when negative results start appearing.
The 5-Fluorouracil Finding, and the p53 Condition Attached to It
The most clinically interesting colorectal result is a 2021 study in Redox Biology.[3] Advanced colorectal cancer often stops responding to 5-fluorouracil, and one route to that resistance is elevated thymidylate synthase, the enzyme 5-fluorouracil targets. When thymidylate synthase goes up, sensitivity goes down.
The researchers screened candidate compounds against two human colorectal lines: HCT116, which carries wild-type p53, and HT29, which carries mutant p53. Apigenin enhanced the effect of 5-fluorouracil on viability and, notably, blocked the upregulation of thymidylate synthase that 5-fluorouracil itself induces. It also reduced viability in 5-fluorouracil-resistant HCT116 cells.
Then comes the condition. The authors state that apoptosis induction was mainly dependent on functional p53. TP53 is among the most commonly mutated genes in colorectal cancer, altered in a large share of tumors. A mechanism that requires intact p53 is a mechanism that would not be expected to work in a substantial fraction of the patients who most need a way around 5-fluorouracil resistance. That is a real limitation on the finding, and it sits in the paper rather than in the summaries of it.
A Direct Molecular Target
A 2023 study in the Journal of Nutritional Biochemistry went looking for where apigenin binds rather than what it correlates with.[4] Anti-colorectal activity tracked positively with pyruvate kinase M2 expression: knocking down PKM2 in LS-174T cells changed how the cells responded to apigenin.
Pull-down experiments and mass spectrometry indicated direct interaction with PKM2, and the work identified lysine residue 433 as the key binding site. Apigenin restricted glycolysis in two colorectal lines by acting at that site, with anti-tumor effects reported both in cells and in animals, and the authors note tumor growth was attenuated without adverse effects.
Identifying a specific amino acid residue is stronger evidence than a pathway diagram. PKM2-driven glycolysis is a legitimate cancer target. What this does not establish is whether an oral dose produces enough free apigenin at a tumor to engage that site. Human pharmacokinetic work found free apigenin poorly absorbed, with urinary metabolite recovery around 0.5 percent of intake and circulating levels dominated by glucuronide and sulfate conjugates rather than the free compound.[5]
The Only Human Data Are About Food, and They Are Oddly Specific
One meta-analysis in this area does involve people. A 2018 analysis in Nutrients pooled 12 epidemiological studies, five cohort and seven case-control, covering 17,481 cases and 740,859 controls, comparing highest against lowest dietary flavonoid intake.[6]
The site-specific results are the interesting part. For flavones, the subclass apigenin belongs to, higher intake was associated with lower rectal cancer risk, with an odds ratio of 0.82 and a 95 percent confidence interval of 0.70 to 0.97. For colon cancer specifically, flavones showed 0.88 with an interval of 0.69 to 1.13, which crosses 1 and is therefore not statistically significant. Flavonols such as quercetin showed the opposite split: associated with lower colon cancer risk at 0.80 with an interval of 0.68 to 0.94, but not with rectal cancer.
Three caveats matter before this gets read as support for supplementation. These are observational associations, not randomized results, and higher flavone intake means more parsley, celery, chamomile and vegetables generally, which travels with other dietary and lifestyle patterns. Dietary intake and isolated capsule intake are not equivalent exposures, and the pharmacokinetic work found the glycoside forms in food are absorbed far better than free apigenin. And a split where flavones associate with rectal but not colon cancer, and flavonols with the reverse, is either a genuinely site-specific biological effect or statistical noise in subgroup analysis. The paper does not resolve which.
How This Differs From the Breast and Prostate Research
Apigenin has separate preclinical literatures in breast and prostate cancer, and those questions do not transfer. Colorectal work centers on glycolysis and PKM2, thymidylate synthase and chemotherapy sensitivity, and the colitis to cancer transition in inflamed bowel. Hormone-responsive cancers bring in estrogen receptor and androgen pathways that are not part of the colorectal story.
There is one bridge worth naming. Chronic colonic inflammation raises colorectal cancer risk, and colitis-associated carcinoma appears in the animal meta-analysis as its own category. That links the colitis research to this one mechanistically, without either becoming evidence for the other.
The Practical Position
Colorectal cancer is curable at early stage and survival falls sharply with delay, which makes screening and treatment timing the highest value decisions available. Nothing in this literature competes with a colonoscopy.
The 5-fluorouracil result deserves a specific warning rather than a general one. Someone on 5-fluorouracil or capecitabine who reads that apigenin potentiates their chemotherapy may treat that as a reason to add it. Modulating thymidylate synthase, the exact target of the drug, is a pharmacodynamic interaction. Apigenin also inhibits several cytochrome P450 enzymes, which affects drug metabolism more broadly. Potentiating a cytotoxic drug is not automatically desirable, since toxicity potentiates alongside efficacy, and dose adjustment during chemotherapy is not something to attempt from a supplement label. This belongs in front of a medical oncologist.
Bottom Line
Apigenin has a large, mechanistically detailed colorectal cancer literature with two named molecular targets: PKM2 at lysine 433, and thymidylate synthase suppression that potentiates 5-fluorouracil. It also has two meta-analyses whose titles read clinical and whose contents are cells and animals, one of which flags its own publication bias. The 5-fluorouracil effect depends on functional p53, which many colorectal tumors lack. The only human evidence is dietary and observational, and it associates flavone intake with lower rectal but not colon cancer risk. No person with colorectal cancer has been studied taking apigenin.
Frequently Asked Questions
Is there human evidence that apigenin helps colorectal cancer?
No clinical trial exists. The two systematic reviews with meta-analyses on this topic pool in vitro and animal studies, not patients, and the 2024 analysis states that further animal work is needed before translation into clinical studies. The only human data are observational dietary studies of flavonoid intake.
Does apigenin interact with 5-fluorouracil chemotherapy?
In colorectal cancer cells apigenin suppressed thymidylate synthase, the enzyme 5-fluorouracil targets, and potentiated the drug including in resistant cells. That is a pharmacodynamic interaction with the drug target, and apigenin also inhibits several cytochrome P450 enzymes. Potentiating a cytotoxic drug increases toxicity as well as efficacy, so this requires oncologist involvement rather than self-supplementation.
Why did the p53 status of the cancer cells matter?
The 2021 study tested HCT116 cells with wild-type p53 and HT29 cells with mutant p53, and reported that apoptosis induction by apigenin plus 5-fluorouracil was mainly dependent on functional p53. TP53 is mutated in a large share of colorectal tumors, so the mechanism would not be expected to operate in many patients.
References
- Ahmadzadeh K, Roshdi Dizaji S, Ramezani F, et al. Potential therapeutic effects of apigenin for colorectal adenocarcinoma: A systematic review and meta-analysis. Cancer Medicine (2024). PMID 39254067
- Singh D, Gupta M, Sarwat M, Siddique HR. Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models. Critical Reviews in Oncology and Hematology (2022). PMID 35752426
- Yang C, Song J, Hwang S, et al. Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells. Redox Biology (2021). PMID 34562873
- Shi J, Ji X, Shan S, et al. The interaction between apigenin and PKM2 restrains progression of colorectal cancer. Journal of Nutritional Biochemistry (2023). PMID 37597817
- Borges G, Fong RY, Ensunsa JL, et al. Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free Radical Biology and Medicine (2022). PMID 35452808
- Chang H, Lei L, Zhou Y, Ye F, Zhao G. Dietary flavonoids and the risk of colorectal cancer: An updated meta-analysis of epidemiological studies. Nutrients (2018). PMID 30041489
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
